Results 211 to 220 of about 74,852 (258)

Patient-derived organoids predict responses to chemotherapy and PARP inhibitors in advanced ovarian cancer. [PDF]

J Transl Med
Wang H, Wang L, Zhu X, He M, Zhong L, Lv Y, Li Q, Jiang Q, Zhang C, Liu X, Zou D.   +10 more
europepmc   +1 more source

Exosome Secretion Drives Chemo‐Resistance of Temozolomide in Glioblastoma

Journal of Extracellular Biology, Volume 5, Issue 7, July 2026.
ABSTRACT Temozolomide (TMZ) is a first‐line chemotherapeutic agent for the treatment of glioblastoma (GBM), while a majority of patients do not effectively respond to TMZ owing to the multiple resistance mechanisms. In this study, we found that TMZ treatment substantially increased the exosome secretion from GBM cell line.
Wenpei Li, Shaoping Jiang, Kun Liu, Zhi Li, Jun Yang, Weimin Liu, Yuanyu Huang, Minghui Yang, Shuai Guo, Shaobo Ruan   +9 more
wiley   +1 more source

Vitamin‐Responsive Disorders: From Molecular Basis to Clinical Presentation and Therapy

Journal of Inherited Metabolic Disease, Volume 49, Issue 4, July 2026.
ABSTRACT Vitamin‐dependent cofactors are essential for numerous metabolic reactions, and defects affecting their uptake, conversion, utilisation, or regeneration constitute a heterogeneous group of inherited metabolic disorders (IMDs). Although dietary vitamin intake is sufficient to sustain coenzyme synthesis in healthy individuals, it is insufficient
Cécile Acquaviva, Yann Nadjar, Manuel Schiff, Christine Vianey‐Saban, Alain Fouilhoux, Jean‐François Benoist   +5 more
wiley   +1 more source

Correction: PARP inhibitors‑associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group. [PDF]

Clin Transl Oncol
Sánchez Cánovas M, López Robles J, García Verdejo FJ, Cacho Lavin D, Olivares H, Garrido Fernández A, Coma Salvans E, Quintanar Verduguez T, Salvador Coloma C, Fernández Garay D, Cumplido JD, Ferrer Pérez AI, Carbó Bagué A, Teigell Muñoz FJ, García López R, Martínez Marin A, Muñoz Martín AJ.   +16 more
europepmc   +1 more source

Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy

MedComm, Volume 7, Issue 7, July 2026.
Tumor progression is driven by heterogeneity occurring across multiple biological scales. At the molecular level, tumor cells exhibit alterations across distinct omics layers, including genomic mutations, epigenomic reprogramming, transcriptional changes, and proteomic remodeling, collectively shaping tumor cell phenotypes and functional states.
Hanwen Hu, Zhixing Hao, Lili Li, Huiying Liu, Chenghui Yang, Zhen Wang   +5 more
wiley   +1 more source

Toxicities of PARP inhibitors in genitourinary cancers. [PDF]

Curr Opin Urol
Szalontai J, Szarvas T, Miszczyk M, Nyirády P, Shariat SF, Fazekas T.   +5 more
europepmc   +1 more source

Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?

Medicinal Research Reviews, Volume 46, Issue 4, Page 1111-1151, July 2026.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca, Mariana Feijó, Cátia V. Vaz, Bruno J. Pereira, Sandra Laurentino, Ana Palmeira‐de‐Oliveira, Sílvia Socorro   +6 more
wiley   +1 more source

Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation. [PDF]

PeerJ
Fan J, Song Y.
europepmc   +1 more source